A Phase 3 interventional study of FE 999049 + GnRH agonist (GONAPEPTYL) and FE 999049 + GnRH antagonist (CETROTIDE) in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 16 sites in 7 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Infertility, Female with a site in Israel — none open to participants now, none under way, none of them phase 3. Infertility, Female · Israel.
Among the 12 studies in Infertility, Female with a site in Israel, this one is one of 2 that started in 2019, is one of 2 in phase 3, and was the 9th registered.
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
Browse Infertility, Female studies →None of the 12 studies in Infertility, Female with a site in Israel is open now. The open studies under Infertility, Female, anywhere →
Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 437 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 60 across the 8 interventional studies, 30 across the 3 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
Ferring Pharmaceuticals has 9 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Infertility, Female with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FE 999049 + GnRH agonist (GONAPEPTYL)
Drug: FE 999049 + GnRH antagonist (CETROTIDE)
Drug pages: Follitropin delta · Gonadotropin-releasing Hormone Analog
Pre-filled injection pen
Drug page: Cetrorelix
Powder and solvent for solution for injection
Number of Oocytes Retrieved
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response
For each participant, the reason for cycle cancellation was recorded
Time frame: At end-of-stimulation (up to 20 days)
Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS)
For each participant, the reason for blastocyst transfer cancellation was recorded.
Time frame: At end of transfer (up to 4 weeks)
Number of Follicles
The total number of follicles and the number of follicles per size category will be reported
Time frame: On stimulation day 6 and at end-of-stimulation (up to 20 days)
Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
Grouped according to number of oocytes
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Number of Metaphase II Oocytes
Only applicable for those inseminated using ICSI
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Fertilization Rate
Measured by the number of pronuclei. Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Number of Embryos
The number of embryos (total and good-quality) was reported. Embryo quality is determined by combined assessment of cleavage stage (number of blastomeres/compaction status) and embryo morphology parameters
Time frame: On day 3 after oocyte retrieval (up to 25 days after start of stimulation)
Number of Blastocysts
The number of blastocysts (total and good-quality) was reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells)
Time frame: On day 5 after oocyte retrieval (up to 27 days after start of stimulation)
Circulating Concentrations of Follicle-stimulating Hormone (FSH)
Blood samples for analysis of circulating concentrations of FSH were drawn.
Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Luteinizing Hormone (LH)
Blood samples for analysis of circulating concentrations of LH were drawn
Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Estradiol
Blood samples for analysis of circulating concentrations of estradiol were drawn
Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Progesterone
Blood samples for analysis of circulating concentrations of progesterone were drawn
Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Inhibin B
Blood samples for analysis of circulating concentrations of Inhibin B were drawn
Time frame: On stimulation day 6, at end-of-stimulation (up to 20 days after start of stimulation) and at oocyte retrieval (up to 22 days after start of stimulation)
Total Gonadotropin Dose
Calculated by start dates, end dates and daily dose of investigational medicinal product
Time frame: Up to 20 days
Number of Stimulation Days
Calculated by start dates and end dates
Time frame: Up to 20 days
Positive Beta Human Chorionic Gonadotropin (βhCG) Rate
Defined as positive serum βhCG test
Time frame: 13-15 days after transfer (up to approximately 1.5 months after start of stimulation)
Implantation Rate
Defined as the number of gestational sacs after transfer divided by number of blastocysts transferred
Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Clinical Pregnancy Rate
Defined as at least one gestational sac
Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Vital Pregnancy Rate
Defined as at least one intrauterine gestational sac with fetal heart beat
Time frame: 5-6 weeks after transfer (up to approximately 2.5 months after start of stimulation)
Ongoing Pregnancy Rate
At least one intrauterine viable fetus
Time frame: 10-11 weeks after transfer (up to approximately 4 months after start of stimulation)
Ongoing Implantation Rate
Defined as number of intrauterine viable fetuses divided by the number of blastocysts transferred
Time frame: 10-11 weeks after transfer (up to approximately 4 months after start of stimulation)
Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
Time frame: Up to 9 days after triggering of final follicular maturation
Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
Time frame: >9 days after triggering of final follicular maturation
Frequency of Adverse Events
Any untoward medical occurrence
Time frame: From time of signing informed consent until the end-of-trial (approximately 7 months)
Intensity of Adverse Events
Categorized as mild, moderate or severe
Time frame: From time of signing informed consent until the end-of-trial (approximately 7 months)
Technical Malfunctions of the Pre-filled Injection Pen
Incidences of technical malfunctions of the pre-filled injection pen were recorded
Time frame: Up to 20 days
The trial was opened for recruitment in April 2019, and participants were assessed at 16 investigational sites in 7 countries between May 2019 and Feb 2022.
| Milestone | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Started | 220 | 215 |
| Completed | 192 | 195 |
| Not completed | 28 | 20 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Adverse event | 6 | 9 |
| Withdrew: Covid-19 | 3 | 1 |
| Withdrew: Participant was discontinued by investigator | 12 | 7 |
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
| Oocytes | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Number of Oocytes Retrieved | 11.1 ± 5.9 | 9.6 ± 5.5 |
For each participant, the reason for cycle cancellation was recorded
| participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Excessive response | 2 | 3 |
| Poor response | 1 | 3 |
| Other reason | 1 | 1 |
For each participant, the reason for blastocyst transfer cancellation was recorded.
| participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Transfer cancellation | 27 | 30 |
| Reason for transfer cancellation: Adverse Event | 5 | 8 |
| Reason for transfer cancellation: Risk of OHSS | 1 | 1 |
| Reason for transfer cancellation: No blastocyst | 13 | 18 |
| Reason for transfer cancellation: COVID-19 | 3 | 1 |
| Reason for transfer cancellation: Other reason | 5 | 2 |
The total number of follicles and the number of follicles per size category will be reported
| Number of follicles | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Total number of follicles at Stimulation Day 6 | 15.2 ± 6.3 | 14.9 ± 6.3 |
| Follicles >= 10 mm at Stimulation Day 6 | 4.6 ± 4.3 | 7.1 ± 3.6 |
| Follicles >= 12 mm at Stimulation Day 6 | 1.6 ± 2.7 | 3.8 ± 2.9 |
| Total number of follicles at End-of-stimulation visit | 18.3 ± 7.1 | 17.1 ± 8.0 |
| Follicles >= 10 mm at End-of-stimulation visit | 14.8 ± 6.4 | 13.3 ± 6.1 |
| Follicles >= 12 mm at End-of-stimulation visit | 12.2 ± 5.3 | 10.9 ± 5.1 |
| Follicles >= 15 mm at End-of-stimulation visit | 7.9 ± 3.7 | 7.2 ± 3.3 |
| Follicles >= 17 mm at End-of-stimulation visit | 4.8 ± 2.1 | 4.6 ± 2.0 |
Grouped according to number of oocytes
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| <4 Oocytes Retrieved | 13 | 26 |
| 4-7 Oocytes Retrieved | 47 | 56 |
| 8-14 Oocytes Retrieved | 84 | 82 |
| 15-19 Oocytes Retrieved | 42 | 29 |
| >=20 Oocytes Retrieved | 16 | 11 |
Only applicable for those inseminated using ICSI
| MII oocytes | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Number of Metaphase II Oocytes | 9.2 ± 4.8 | 7.9 ± 4.7 |
Measured by the number of pronuclei. Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized
| percentage of fertilized oocytes | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Fertilization Rate | 53.8 ± 24.1 | 54.4 ± 26.8 |
The number of embryos (total and good-quality) was reported. Embryo quality is determined by combined assessment of cleavage stage (number of blastomeres/compaction status) and embryo morphology parameters
| Embryos | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Total number of embryos | 5.7 ± 3.9 | 5.0 ± 3.9 |
| Number of good-quality embryos | 4.0 ± 3.2 | 3.9 ± 3.3 |
The number of blastocysts (total and good-quality) was reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells)
| Blastocysts | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Total Number of blastocysts | 3.8 ± 3.1 | 3.3 ± 2.9 |
| Number of good-quality blastocysts | 2.3 ± 2.3 | 2.1 ± 2.2 |
Blood samples for analysis of circulating concentrations of FSH were drawn.
| IU/L | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Stimulation Day 6 | 15.5 ± 4.3 | 16.7 ± 4.5 |
| End-of-stimulation | 16.2 ± 4.4 | 15.8 ± 4.0 |
| Oocyte retrieval | 9.4 ± 2.8 | 9.8 ± 2.9 |
Blood samples for analysis of circulating concentrations of LH were drawn
| IU/L | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Stimulation Day 6 | 1.5 ± 0.9 | 5.6 ± 6.0 |
| End-of-stimulation | 1.8 ± 0.9 | 1.8 ± 1.5 |
| Oocyte retrieval | 0.2 ± 0.2 | 2.0 ± 2.1 |
Blood samples for analysis of circulating concentrations of estradiol were drawn
| pmol/L | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Stimulation Day 6 | 1190.1 ± 1101.2 | 2675.8 ± 1544.3 |
| End-of-stimulation | 7542.7 ± 4106.8 | 6487.7 ± 3960.2 |
| Oocyte retrieval | 3485.1 ± 2129.0 | 3163.5 ± 1865.0 |
Blood samples for analysis of circulating concentrations of progesterone were drawn
| nmol/L | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Stimulation Day 6 | 1.8 ± 1.0 | 2.6 ± 1.5 |
| End-of-stimulation | 3.1 ± 1.4 | 3.5 ± 2.0 |
| Oocyte retrieval | 25.9 ± 12.9 | 26.0 ± 13.2 |
Blood samples for analysis of circulating concentrations of Inhibin B were drawn
| pg/mL | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Stimulation Day 6 | 690.4 ± 419.1 | 808.2 ± 428.5 |
| End-of-stimulation | 1032.6 ± 605.2 | 938.1 ± 570.0 |
| Oocyte retrieval | 416.6 ± 253.9 | 389.0 ± 226.6 |
Calculated by start dates, end dates and daily dose of investigational medicinal product
| ug | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Total Gonadotropin Dose | 112.2 ± 28.9 | 96.5 ± 26.0 |
Calculated by start dates and end dates
| Days | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Number of Stimulation Days | 10.4 ± 1.9 | 8.8 ± 1.8 |
Defined as positive serum βhCG test
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Positive βhCG test | 91 | 79 |
| Negative βhCG test | 111 | 125 |
Defined as the number of gestational sacs after transfer divided by number of blastocysts transferred
| Embryos | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Implantation Rate | 82 | 68 |
Defined as at least one gestational sac
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Positive | 81 | 68 |
| Negtaive | 121 | 136 |
Defined as at least one intrauterine gestational sac with fetal heart beat
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Positive | 77 | 62 |
| Negative | 125 | 142 |
At least one intrauterine viable fetus
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Positive | 73 | 60 |
| Negative | 129 | 144 |
Defined as number of intrauterine viable fetuses divided by the number of blastocysts transferred
| Embryos | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Ongoing Implantation Rate | 74 | 60 |
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade) | 8 | 5 |
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) | 4 | 6 |
Any untoward medical occurrence
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Frequency of Adverse Events | 112 | 109 |
Categorized as mild, moderate or severe
| Percentage of participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Mild adverse events | 42.6 | 41.7 |
| Moderate adverse events | 18.8 | 16.7 |
| Severe adverse events | 4.0 | 3.4 |
Incidences of technical malfunctions of the pre-filled injection pen were recorded
| Participants | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Technical Malfunctions of the Pre-filled Injection Pen | 2 | 0 |
Collected over Adverse events were recorded from signing of the informed consent until end-of-trial (approximately 7 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 + GnRH Agonist (GONAPEPTYL) | 0/202 (0%) | 4/202 (2%) | 68/202 (33.7%) |
| FE 999049 + GnRH Antagonist (CETROTIDE) | 0/204 (0%) | 6/204 (2.9%) | 69/204 (33.8%) |
| Event | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 2/202 | 4/204 |
| AppendicitisInfections and infestations | 1/202 | 0/204 |
| Bacterial abdominal infectionInfections and infestations | 1/202 | 0/204 |
| Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions | 0/202 | 1/204 |
| Adnexal torsionReproductive system and breast disorders | 0/202 | 1/204 |
| Event | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) |
|---|---|---|
| HeadacheNervous system disorders | 27/202 | 29/204 |
| Procedural painInjury, poisoning and procedural complications | 20/202 | 12/204 |
| Pelvic painReproductive system and breast disorders | 14/202 | 11/204 |
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 12/202 | 11/204 |
| Biochemical pregnancyPregnancy, puerperium and perinatal conditions | 10/202 | 11/204 |
| Age, Continuous(years) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| Mean | 32.3 ± 4.4 | 32.4 ± 4.2 | 32.3 ± 4.3 |
| Age, Customized(Participants) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| <35 years | 143 | 141 | 284 |
| 35-37 years | 47 | 48 | 95 |
| 38-40 years | 30 | 26 | 56 |
| Sex: Female, Male(Participants) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| Female | 220 | 215 | 435 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 211 | 205 | 416 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 9 | 8 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 208 | 202 | 410 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| Austria | 29 | 31 | 60 |
| Netherlands | 31 | 26 | 57 |
| Norway | 117 | 114 | 231 |
| Denmark | 15 | 16 | 31 |
| Italy | 9 | 12 | 21 |
| Israel | 13 | 12 | 25 |
| Switzerland | 6 | 4 | 10 |
| Body Mass Index (BMI)(kg/m^2) | FE 999049 + GnRH Agonist (GONAPEPTYL) | FE 999049 + GnRH Antagonist (CETROTIDE) | Total |
|---|---|---|---|
| Mean | 24.36 ± 3.50 | 24.39 ± 3.55 | 24.37 ± 3.52 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Feb 2022, 33 months.
Results were first posted in May 2024, 2 years 2 months after primary completion.
Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 33 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Follitropin delta · Gonadotropin-releasing Hormone Analog